The drug being tested in this study is called TAK-931. TAK-931 blocks the function of a specific protein in the body called CDC7 kinase. TAK-931 is being tested in participants with metastatic pancreatic cancer or metastatic colorectal cancer plus a cohort of US patients with metastatic cancer with no other standard therapeutic alternative. This study will look at safety, tolerability and pharmacokinetics of TAK-931 in people who take TAK-931.